The present invention concerns a method of generating a population of skeletal muscle derived human muscle precursor cells. For this purpose, a specialized FBS-free cell growth medium is used. The invention further concerns a composition comprising such a population of hMPCs for use as a medicament, especially in the treatment of skeletal muscle dysfunction.

The present disclosure relates to compositions and methods for improving wound healing and tissue regeneration. More specifically, the present disclosure relates to compositions, and methods of using such compositions, that direct the immune response within a wound towards a pro-regenerative response. Such compositions and methods are particularly useful in altering the immune response elicited by medical implants, to avoid scarring and fibrosis at the site of implantation.

A polyethylene glycol (PEG) prepolymer is disclosed herein. The PEG prepolymer comprises a reaction product of an amine-reactive PEG and a protease degradable peptide. The reaction product comprises the formula [Acryl-PEG-peptide-PEGAcryl].sub.n, wherein n is greater than 0. The reaction product can be combined with a thiolated biomolecule. Matrices formed from the PEG prepolymer and the thiolated biomolecule are provided and uses thereof.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases/disorders and rheumatic diseases/disorders.

The present invention relates to the use of collagen hydrolysate in the prevention and/or treatment of food craving. The collagen hydrolysate may have a therapeutic and/or non-therapeutic effect. The prevention and/or treatment of craving by the collagen hydrolysate may find purpose in losing bodyweight or improving general well-being. The collagen hydrolysate is preferably administered as a daily food supplement formulation.

Described herein are compositions and methods for treating ischemic injury in a subject comprising administering a therapeutically effective amount of an acellular amniotic fluid (acAF) to an ischemic injury situs within a therapeutic time window.

A composition is provided that includes hydrolyzed collagen, at least one biguanide, at least one vicinal diol, and at least one chelating agent. The composition exhibits at least 2-log reduction of planktonic microbes within 24 hours. Methods of using the composition are also provided.

This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection. The composition includes phytocannabinoids such as CBG and CBC, along with hyaluronic acid, type II collagen, and calcium gluconate, embedded within a nanoplatform designed to enhance bioavailability and ensure controlled release in the synovial space. Tailored for osteoarthritis patients, the treatment alleviates joint pain, stiffness, reduced mobility, inflammation, sensations of friction, muscle weakness, and joint deformity. Cannabinoids act through multiple mechanisms, including interaction with CB1 and CB2 receptors, cytokine modulation, inhibition of NF-B, and activation of the TRPV1 receptor, providing a potent anti-inflammatory effect. The formulation aims to halt cartilage degeneration, reduce pain, and slow osteoarthritis progression. The production process uses nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration, ensuring both efficacy and safety.

The present disclosure relates to compositions comprising collagen 7 and methods of using the same to treat DEB.